Market News How it works Learn FAQ
| GPUS 0.1689 34.05% | XXII 0.1977 -8.34% | SHFS 0.1324 -61.39% | NVD 4.19 0.96% | LUCD 0.411 25.42% | SPCX 147.49 1.89% | T 20.93 -7.96% | SOXL 83.56 1.77% | NU 15.16 2.92% | NOK 8.14 3.30% | EWZ 42.59 1.77% | NVDA 210.96 -0.59% | RIME 0.106 -12.90% | INTC 86.96 1.72% | TSLG 4.87 -1.62% | AAL 12.11 -3.89% | BBD 4.07 3.04% | STLA 4.06 -4.81% | SOXS 52.46 -1.85% | RWM 14.55 0.34% | HYG 77.05 -0.06% | MYND 0.24 47.42% | BITO 10.83 -0.28% | SPDN 8.54 0.47% | YFOR 0.2236 -1.58% | RBNE 0.19 -2.56% | TQQQ 66.29 -0.20% | VZ 44.66 -1.19% | TSLL 9.76 -1.21% | SPTI 27.63 -0.11% | YMAT 2.05 6.77% | CRWV 54.235 -2.46% | INFY 12.35 -6.58% | RIG 6.41 5.43% | F 11.6 -2.85% | SQQQ 39.68 0.20% | AIOK 12.02 182.82% | ONDS 6.2 2.99% | AAPL 347.725 -0.14% | LABT 0.31 -36.67% | CDE 13.45 -3.10% | PCG 12.63 -2.70% | GRAB 2.79 -2.11% | SOFI 14.615 -1.05% | XLE 69.33 2.60% | IREN 24.905 -2.37% | QID 14.55 0.14% | RKT 11.73 -0.09% | WULF 11.32 0.00% | BE 193.3 -11.24%
PRProthena Corporation plc logo

Prothena Corporation plc (PRTA)

NASDAQ · Currency in USD
$8.20 ▼ -0.05 (-0.61%)
At close: Oct 23, 4:00 PM ET. Market closed.
$9.10 ▲ +0.90 (+10.98%)
After hours: Oct 23, 7:30 PM ET

Summary

Previous Close
$8.25
Open
$8.18
Day's Range
$7.94 – $8.26
52 Week Range
$7.73 – $11.80
Volume
385,913
Avg. Volume
520,624
Market Cap
$420.96M
Beta (5Y Monthly)
-0.33
PE Ratio (TTM)
--
EPS (TTM)
-$0.84
Earnings Date
Nov 5, 2026
Forward Dividend & Yield
--
Ex-Dividend Date
--
1y Target Est
$30.00

Profile: Prothena Corporation plc

Sector
Healthcare
Industry
Biotechnology
Full-time employees
67
CEO
Gene G. Kinney

Prothena Corporation plc, a late-stage clinical biotechnology company, focuses on discovery and development of novel therapies to treat diseases caused by protein dysregulation. Its product pipeline includes Prasinezumab, an investigational humanized monoclonal antibody which is in Phase 3 clinical trial for the treatment of parkinson's disease and other synucleinopathies. The company also develops Coramitug, an investigational antibody, which is in Phase 3 clinical trial for the treatment of transthyretin amyloidosis; BMS-986446, an anti-tau antibody which is in Phase 2 clinical trial to treat Alzheimer's disease; PRX019, an investigational antibody which is in Phase 1 clinical trial for the treatment of neurodegenerative diseases; and PRX123, a Dual Aß-Tau Vaccine, which is in preclinical trial for treating Alzheimer's disease.

Earnings

Next report: Thu, Nov 5, 2026
EPS estimate -$0.21 · Revenue est. $9.58M
DateEst.Actual
Aug 6, 2026-$0.39-$0.32Beat
May 7, 2026-$0.31$0.60Beat
Feb 19, 2026-$0.45-$0.44Beat
Nov 6, 2025-$0.60-$0.67Miss
Aug 4, 2025-$1.11-$1.86Miss
May 8, 2025-$0.92-$1.12Miss

Analyst view

Consensus price target
$30.00 ▲ +265.9%
Range $30.00 – $30.00
Rating: Buy
Buy 71% · Hold 21% · Sell 7%

Get free alerts on PRTA and big market moves

Free special alerts by text & email on new investment opportunities, buyouts and the stocks moving most, in plain English.
Get free stock alerts →
Data: Financial Modeling Prep. For information only, not investment advice.